Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
2006-12-05
2006-12-05
Badio, Barbara P. (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
C552S548000, C552S550000, C552S551000
Reexamination Certificate
active
07144877
ABSTRACT:
Disclosed are methods for providing enhanced systemic blood concentrations of orally delivered drugs that are incompletely translocated across the intestinal wall of an animal. Also disclosed are methods for the sustained release of drugs, whether poorly or readily bioavailable via oral delivery to animals. Still further, disclosed are compounds and pharmaceutical compositions that are used in such methods.
REFERENCES:
patent: 3326758 (1967-06-01), Irmscher et al.
patent: 4560512 (1985-12-01), Firestone
patent: 5352682 (1994-10-01), Sipos
patent: 5462933 (1995-10-01), Kramer et al.
patent: 5646272 (1997-07-01), Kramer et al.
patent: 5668126 (1997-09-01), Kramer et al.
patent: 5695738 (1997-12-01), Anderson et al.
patent: 5725840 (1998-03-01), Klaveness et al.
patent: 5942248 (1999-08-01), Barnwell
patent: 6143738 (2000-11-01), Zasloff
patent: 6288041 (2001-09-01), Chaki et al.
patent: 04059792 (1992-02-01), None
patent: 11-60594 (1999-03-01), None
patent: WO 94/29336 (1994-12-01), None
patent: WO 99/41275 (1999-08-01), None
patent: WO 01/09163 (2001-02-01), None
patent: WO 01/76531 (2001-10-01), None
patent: WO 02/32376 (2002-04-01), None
patent: 02/100347 (2002-12-01), None
Database esp@cenet on STN, PN KR9701149 (Kim Young-Man et al.), Jan. 29, 1997, Abstract only.
Swaan et al., Preface. Advanced Drug Delivery Reviews. 1996, vol. 20, pp. 1-3.
Russell-Jones et al., “Vitamin B12 Mediated Oral Delivery Systems for Granulocyte-Colony Stimulating Factor and Erythropoietin,”Bioconjugate Chemistry, 1995, vol. 6, pp. 459-465.
Shah et al., “Transcellular Delivery of an Insulin-Transferrin Conjugate in Enterocyte-like Caco-2 Cells,”J. of Pharm. Sci., Dec. 1996, vol. 85, No. 12, pp. 1306-1311.
International Search Report mailed Jan. 22, 2002 from PCT/US01/42513.
International Search Report mailed Jan. 23, 2002 from PCT/US01/31486.
International Search Report mailed Dec. 31, 2001 from PCT/US01/31394.
European Search Report from EP 01 98 9083 dated May 25, 2005.
Kramer et al., “Modified Bile Acid as Carriers for Peptides and Drugs”, Journal of Controlled Release, vol. 46, (1997), Amsterdam, NL, pp. 17-30.
Lee et al., “Pharmacogenomics of Drug Transporters: The Next Drug Delivery Challenge”, Advanced Drug Delivery Reviews, vol. 50, (2001), pp. S33-S40.
European Search Report dated May 26, 2005.
Anelli et al.,Synth. Commun. 1998, 28, pp. 109-117.
Baringhaus, K.H., et al., Substrate specificity of the ileal and hepatic Na+/ bile acid cotransporters of the rabbit. II. A reliable 3D QSAR pharmacophore model for the ileal Na/bile acid cotransporter,J. Lipid Res. 1999, 40, pp. 2158-2168.
Batta, et al.,J. Lipid. Res. 1991, 32, 977-983.
Bundgaard, H., inDesign of Prodrugs(Bundgaard, H. Ed.), Elsevier Science B.V., 1985, pp. 1-92.
Bundgaard, H., et al., Esters of N, N-disubstituted 2-hydroxyacetamides as a novel highly biolabile prodrug type for carboxylic acids,J. Med. Chem., 1987, 30, pp. 451-454. Copy needed.
Ho, N. F. H., Utilizing bile acid carrier mechanisms to enhance liver and small intestine absorption,Ann. N. Y. Acad. Sci., 1987, 507, pp. 315-329.
Kagedahl, M., et al., Use of the intestinal bile acid transporter for the uptake of cholic acid conjugates with HIV-1 protease inhibitory activity,Pharm. Res., 1997., 14, pp. 176-180.
Kim, D.C., et al., Evaluation of bile acid transporter in enhancing intestinal permeability of renin-inhibitory peptides,J. Drug Targeting, 1993, 1, pp. 347-359.
Kramer, W., et al., Liver-specific drug targeting by coupling to bile acids,J. Biol. Chem., 1992, 267, pp. 18598-18604.
Kramer, W., et al.,. Intestinal absorbtion of peptides by coupling to bile acids,J. Biol. Chem., 1994a, 269, pp. 10621-10627.
Kramer, W., et al., Bile acid derived HMG-CoA reductase inhibitors,Biochim. Biophys. Acta, 1994b, 1227, 137-154.
Kramer, W., et al., Substrate specificity of the ileal and hepatic Na+/ bile acid cotransporters of the rabbit. I. Transport studies with membrane vesicles and cell lines expressing the cloned transporters,J. Lipid Res. 1999, 40, pp. 1604-1617.
Kullak-Ublick, G.A., et al., Hepatobiliary transport,J. Hepatology2000, 32 (Suppl. 1), pp. 3-18.
Navia, M.A., et al., Design principles for orally bioavailable drugs,Drug Discovery Today, 1996, 7, pp. 179-189.
Petzinger, E., et al., Hepatobiliary transport of hepatic 3-hydroxy-3-methylglutaryl coenzyme. A reductase inhibitors conjugated with bile acids,Hepatology1995, 22, pp. 1801-1811.
Swaan, P.W., et al., Use of the intestinal and hepatic bile acid transporters for drug delivery,Adv. Drug Delivery Rev., 1996, 20, pp. 59-82.
Tsuji, A., et al., Carrier-mediated intestinal transport of drugs,Pharm. Res., 1996, 13, pp. 963-977.
Cundy Kenneth C.
Gallop Mark A.
Badio Barbara P.
Buchanan & Ingersoll & Rooney PC
XenoPort, Inc.
LandOfFree
Bile-acid derived compounds for enhancing oral absorption... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Bile-acid derived compounds for enhancing oral absorption..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Bile-acid derived compounds for enhancing oral absorption... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3708204